Health care company Eli Lilly and Company (NYSE:LLY) revealed on Monday that the US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for Taltz injection in 80 mg/ml for the treatment of paediatric patients with moderate to severe plaque psoriasis.
The US FDA has approved the sBLA for the company's Taltz (ixekizumab) injection in 80 mg/ml for the treatment of paediatric patients (ages six to under 18) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
In conjunction, the safety, tolerability and efficacy of Taltz in patients ages six to under 18 was demonstrated in the company's randomized, double-blind, placebo-controlled Phase 3 study that included 171 patients with moderate to severe plaque psoriasis. The patients were randomized to receive Taltz (20 mg for 50 kg through Week 12, with 40 mg, 80 mg or 160 mg starting doses, respectively) or placebo. Taltz met all major secondary endpoints in the study.
According to the company, Taltz (ixekizumab) is a monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Taltz inhibits the release of pro-inflammatory cytokines and chemokines and is the first and only IL-17A antagonist approved for paediatric patients with severe plaque psoriasis
Following the US FDA approval, the company will work with insurers, health systems and providers to ensure patients are able to access the treatment.
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML
Ligand Pharmaceuticals announces presentation of Captisol-enabled Topiramate Injection data